drugset / Trial / NCT04355962

Sevoflurane in COVID-19 ARDS (SevCov)

NCT04355962

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

Timeline

Start
2020-04-23
Primary completion
2021-06-25
Completion
2021-07-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevoflurane Other / unclassified
Comparator Dexmedetomidine Other / unclassified
Comparator Fentanyl Other / unclassified
Comparator Midazolam Small molecule
Comparator Propofol Small molecule